Endonovo Therapeutics Book Value Per Share Growth & History (ENDV)
Endonovo Therapeutics's book value per share was -$0.05 for fiscal 2024.
View full Endonovo Therapeutics company overviewEndonovo Therapeutics annual book value per share history
| Fiscal year | Period ended | Book value per share | Change | Growth |
|---|---|---|---|---|
| 2024 | 2024-12-31 | -$0.05 | $0.03 | — |
| 2023 | 2023-12-31 | -$0.08 | $0.08 | — |
| 2022 | 2022-12-31 | -$0.15 | $0.06 | — |
| 2021 | 2021-12-31 | -$0.21 | $0.37 | — |
| 2020 | 2020-12-31 | -$0.59 | $16.66 | — |
| 2019 | 2019-12-31 | -$17.24 | -$17.22 | — |
| 2018 | 2018-12-31 | -$0.03 | $0.00 | — |
| 2017 | 2017-12-31 | -$0.03 | $0.03 | — |
| 2016 | 2016-12-31 | -$0.06 | $0.02 | — |
| 2015 · Dec 31 | 2015-12-31 | -$0.09 | -$0.03 | — |
| 2014 | 2014-12-31 | -$0.06 | $4.91 | — |
| 2013 | 2013-12-31 | -$4.97 | -$4.93 | — |
| 2012 | 2012-12-31 | -$0.04 | -$0.02 | — |
| 2011 | 2011-12-31 | -$0.01 | -$0.05 | — |
| 2010 | 2010-12-31 | $0.04 | — | — |
Endonovo Therapeutics quarterly book value per share
| Fiscal quarter | Period ended | Book value per share | Change | YoY change |
|---|---|---|---|---|
| Q2 2025 | 2025-06-30 | -$0.02 | — | — |
| Q1 2025 | 2025-03-31 | -$0.02 | — | — |
| Q4 2024 | 2024-12-31 | -$0.05 | — | — |
| Q3 2023 | 2023-09-30 | -$0.07 | $0.05 | — |
| Q2 2023 | 2023-06-30 | -$0.08 | $0.05 | — |
| Q1 2023 | 2023-03-31 | -$0.09 | $0.13 | — |
| Q4 2022 | 2022-12-31 | -$0.15 | $0.06 | — |
| Q3 2022 | 2022-09-30 | -$0.12 | $0.14 | — |
| Q2 2022 | 2022-06-30 | -$0.13 | $0.15 | — |
| Q1 2022 | 2022-03-31 | -$0.22 | $0.09 | — |
| Q4 2021 | 2021-12-31 | -$0.21 | $0.37 | — |
| Q3 2021 | 2021-09-30 | -$0.26 | $0.47 | — |
| Q2 2021 | 2021-06-30 | -$0.28 | $1.41 | — |
| Q1 2021 | 2021-03-31 | -$0.31 | $1.23 | — |
| Q4 2020 | 2020-12-31 | -$0.59 | $16.66 | — |
| Q3 2020 | 2020-09-30 | -$0.74 | $19.12 | — |
| Q2 2020 | 2020-06-30 | -$1.69 | $20.55 | — |
| Q1 2020 | 2020-03-31 | -$1.54 | $20.95 | — |
| Q4 2019 | 2019-12-31 | -$17.24 | -$17.22 | — |
| Q3 2019 | 2019-09-30 | -$19.86 | -$19.82 | — |
| Q2 2019 | 2019-06-30 | -$22.24 | -$22.21 | — |
| Q1 2019 | 2019-03-31 | -$22.49 | -$22.47 | — |
| Q4 2018 | 2018-12-31 | -$0.03 | $0.00 | — |
| Q3 2018 | 2018-09-30 | -$0.04 | $0.01 | — |
| Q2 2018 | 2018-06-30 | -$0.03 | $0.01 | — |
| Q1 2018 | 2018-03-31 | -$0.03 | $0.03 | — |
| Q4 2017 | 2017-12-31 | -$0.03 | $0.03 | — |
| Q3 2017 | 2017-09-30 | -$0.05 | $0.02 | — |
| Q2 2017 | 2017-06-30 | -$0.04 | $0.02 | — |
| Q1 2017 | 2017-03-31 | -$0.06 | — | — |
| Q4 2016 | 2016-12-31 | -$0.06 | $0.02 | — |
| Q2 2016 | 2016-09-30 | -$0.07 | — | — |
| Q1 2016 · Jun 30 | 2016-06-30 | -$0.06 | — | — |
| Q4 2015 | 2015-12-31 | -$0.09 | -$0.03 | — |
| Q1 2015 | 2015-03-31 | -$0.05 | — | — |
| Q4 2014 | 2014-12-31 | -$0.06 | $4.91 | — |
| Q4 2013 | 2013-12-31 | -$4.97 | -$4.93 | — |
| Q3 2013 | 2013-09-30 | -$0.05 | -$0.02 | — |
| Q2 2013 | 2013-06-30 | -$0.05 | -$0.03 | — |
| Q1 2013 | 2013-03-31 | -$0.04 | -$0.02 | — |
| Q4 2012 | 2012-12-31 | -$0.04 | -$0.02 | — |
| Q3 2012 | 2012-09-30 | -$0.03 | — | — |
| Q2 2012 | 2012-06-30 | -$0.02 | — | — |
| Q1 2012 | 2012-03-31 | -$0.01 | — | — |
| Q4 2011 | 2011-12-31 | -$0.01 | — | — |
Endonovo Therapeutics book value per share trends
Over the last five fiscal years, Endonovo Therapeutics's book value per share increased from -$17.24 to -$0.05, a change of $17.19. The latest reported quarter, Q2 2025, shows -$0.02.
What book value per share means
Book value per share estimates the common shareholders’ accounting equity represented by each share. It can help compare a company’s balance-sheet value over time, although market value can differ substantially from book value.
How book value per share is calculated
TickerStat calculates book value per share as SEC-reported common shareholders’ equity divided by reported period-end common shares. Preferred equity is subtracted when separately reported, and basic weighted-average shares are used only when period-end shares are unavailable. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Endonovo Therapeutics source filings ↗